Jane Street Group LLC lowered its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 80.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,852 shares of the company's stock after selling 70,071 shares during the quarter. Jane Street Group LLC's holdings in HealthEquity were worth $1,617,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Arcadia Investment Management Corp MI purchased a new stake in shares of HealthEquity during the 4th quarter worth about $26,000. Transce3nd LLC purchased a new stake in shares of HealthEquity during the 4th quarter worth about $29,000. Smartleaf Asset Management LLC raised its stake in shares of HealthEquity by 34.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after purchasing an additional 98 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of HealthEquity during the 4th quarter worth about $39,000. Finally, UMB Bank n.a. raised its stake in shares of HealthEquity by 65.6% during the 4th quarter. UMB Bank n.a. now owns 414 shares of the company's stock worth $40,000 after purchasing an additional 164 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.
HealthEquity Stock Performance
HQY opened at $98.23 on Monday. The stock has a market cap of $8.50 billion, a PE ratio of 90.12, a P/E/G ratio of 1.60 and a beta of 0.45. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 1 year low of $65.01 and a 1 year high of $115.59. The stock's 50 day simple moving average is $87.88 and its 200-day simple moving average is $97.12.
Analyst Upgrades and Downgrades
HQY has been the topic of a number of recent analyst reports. The Goldman Sachs Group cut their price objective on HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a research note on Thursday, March 27th. Raymond James raised HealthEquity from an "outperform" rating to a "strong-buy" rating and cut their price objective for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Wells Fargo & Company lifted their price target on HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Barrington Research reaffirmed an "outperform" rating and issued a $112.00 price target on shares of HealthEquity in a research report on Friday, April 11th. Finally, KeyCorp dropped their price target on HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, HealthEquity currently has an average rating of "Buy" and an average target price of $111.75.
Read Our Latest Report on HQY
Insider Activity
In related news, EVP Michael Henry Fiore sold 8,881 shares of the business's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the sale, the executive vice president now owns 56,655 shares of the company's stock, valued at $4,433,820.30. The trade was a 13.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert W. Selander sold 5,750 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the sale, the director now directly owns 84,969 shares in the company, valued at approximately $6,597,842.85. This represents a 6.34% decrease in their position. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
